Theoretical and Natural Science

- The Open Access Proceedings Series for Conferences


Theoretical and Natural Science

Vol. 35, 10 July 2024


Open Access | Article

The discovery of osimertinib (AZD9291) for the treatment of lung cancer and its chemistry

Victor Li * 1
1 University High School

* Author to whom correspondence should be addressed.

Theoretical and Natural Science, Vol. 35, 225-236
Published 10 July 2024. © 2023 The Author(s). Published by EWA Publishing
This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Citation Victor Li. The discovery of osimertinib (AZD9291) for the treatment of lung cancer and its chemistry. TNS (2024) Vol. 35: 225-236. DOI: 10.54254/2753-8818/35/20240515.

Abstract

Inhibitors of the epidermal growth factor receptor (EGFR) have been approved as drugs to treat patients with non-small-cell lung cancer (NSCLC). While these medications exhibit good clinical efficacy, a lot of patients acquire treatment resistance due to T790M mutation, causing the disease to advance. Furthermore, these medicines may hit the EGFR wild-type receptor, leading to adverse effects. In this publication, we present the discovery of the medication osimertinib (AZD9291), a mutant-selective agent. The T790M resistant mutant and EGFR sensitizing (or activating, EGFRm+) mutant are both irreversibly inhibited. In addition, it possesses high selectivity to the receptor's wild-type form.

Keywords

osimertinib (AZD9291), epidermal growth factor receptor (EGFR), tyrosine kinase inhibitors, drug resistance, anticancer

References

1. World Health Organization. Cancer Fact Sheet 2017, Available at: http://www.who.int/mediacentre/factsheets/fs297/en/. Accessed: January 7, 2020.

2. Thai, A. A., Solomon, B. J., Sequist, L. V., Gainor, J. F., Heist, R.S. (2021)Lung cancer, Lancet, 398: 535–554.

3. Sharma, S. V., Bell, D. W., Settleman, J., Haber, D. A. (2007) Epidermal growth factor receptor mutations in lung cancer. Nat. Rev. Cancer, 7: 169-181.

4. Mok, T. S., Wu, Y.L., Thongprasert, S., Yang, C.H., Chu, D.T., Saijo, N.,Sunpaweravong, P., Han, B., Margono, B., Ichinose, Y., Nishiwaki, Y., Ohe, Y., Yang, J.J.,Chewaskulyong, B., Jiang, H., Duffield, E. L., Watkins, C. L.,Armour, A. A., Fukuoka, M. (2009) Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N. Engl. J. Med., 361: 947−957.

5. Shepherd, F. A., Pereira, J. R.,Ciuleanu, T., Tan, E. H., Hirsh, V.,Thongprasert, S., Campos, D.,Maoleekoonpiroj, S.; Smylie, M.; Martins, R.; Kooten, M. V.; Dediu, M.; Findlay, B.; Tu, D.; Johnston, D., Bezjak, A., Clark, G., Santabarbara, P., Seymour, L. (2005) Erlotinib in previously treated non-small-cell lung cancer. N. Engl. J. Med., 353: 123−132.

6. Cataldo, V. D., Gibbons, D. L., Perez-Soler, R., Quinta ́ s-́Cardama, A. (2011) Treatment of non−small-cell lung cancer with erlotinib or gefitinib. N. Engl. J. Med., 364: 947−955.

7. Wu, Y.-L., Zhou, C., Hu, C.-P., Feng, J., Lu, S., Huang, Y., Li, W., Hou, M., Shi, J. H., Lee, K.-Y., Xu, C. R., Massey, D., Kim, M., Shi, Y., Geater, S. L. (2014) Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial. Lancet Oncol., 15: 213−222.

8. Hoffknecht, P.,Tufman, A., Wehler, T., Pelzer, T., Wiewrodt, R., Schütz, M., Serke, M., Stohlmacher-Williams, J., Marten, A., Maria Huber, R., Dickgreber, N. J. (2015) Efficacy of the irreversible ErbB family blocker Afatinib in epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI)–Pretreated non–small-cell lung cancer patients with brain metastases or leptomeningeal disease, J. Thorac. Oncol., 10: 156–163.

9. Westover, D., Zugazagoitia, J., Cho, B. C., Lovly, C. M., Paz-Ares, L. (2018) Mechanisms of acquired resistance to first- and second-generation EGFR tyrosine kinase inhibitors, Ann. Oncol., 29: i10–i19.

10. Kim, Y., Ko, J., Cui, Z., Abolhoda, A., Ahn, J. S., Ou, S. H., Ahn, M. J., Park, K. (2012)The EGFR T790M mutation in acquired resistance to an irreversible second-generation EGFR inhibitor, Mol. Cancer Ther., 11: 784–791.

11. Liam, K. (2017) Osimertinib as first-line treatment of EGFR mutant advanced nonsmall cell lung cancer, Lung Cancer Res., 6: S62–S66.

12. Ward, R. A., Anderton, M. J., Ashton, S., Bethel, P. A., Box, M., Butterworth, S., Colclough, N., Chorley, C. G.,Chuaqui, C., Cross, D. A., Dakin, L. A., Debreczeni, J. E., Eberlein, C., Finlay, M. R. V., Hill, G. B., Grist, M.,Klinowska, T. C., Lane, C., Martin, S., Orme, J. P., Smith, P., Wang, F., Waring, M. J. (2013) Structure- and reactivity-based development of covalent inhibitors of the activating and gatekeeper mutant forms of the epidermal growth factor receptor (EGFR). J. Med. Chem., 56: 7025−7048.

13. Abourehab, M. A. S., Alqahtani, A. M., Youssif, B. G. M.,Gouda, A. M. (2021) Globally Approved EGFR Inhibitors: Insights into Their Syntheses, Target Kinases, Biological Activities, Receptor Interactions, and Metabolism. Molecules, 26: 6677

14. Cross, D. A. E., Ashton, S.,Ghiorghiu, S., Eberlein, C.,Nebhan, C.,Spitzler, P., Orme, J., Finlay, M. R. V., Ward, R. A., Mellor, M., Hughes, G., Rahi, A., Jacobs, V., Red Brewer, M., Ichihara, E., Sun, J., Jin, H., Ballard, P., Al-Kadhimi, K., Rowlinson, R.,Klinowska, T., Richmond, G.,Cantarini, M., Kim, D.-W., Ranson, M., Pao, W. (2014) AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer. Cancer Discovery, 4: 1046-1061

15. Xu, L., Xu, B., Wang, J., Gao, Y., He, X., Xie, T., Ye, X. Y. (2023) Recent advances of novel fourth generation EGFR inhibitors in overcoming C797S mutation of lung cancer therapy, Eur. J. Med. Chem., 245: 114900

16. Finlay, M.R.V., Anderton, M., Ashton, S., Ballard, P., Bethel, P.A., Box, M.R., Bradbury, R.H., Brown, S.J., Butterworth, S., Campbell, A. (2014) Discovery of a potent and selective EGFR inhibitor (AZD9291) of both sensitizing and T790M resistance mutations that spares the wild type form of the receptor. J. Med. Chem., 57: 8249–8267.

17. Liu, H.,Lv, Y., Li, Y., Cai, J., Chen, J., Qin, Y., Ji, M.(2015)J. Chem. Res., 39: 318-320.

18. Zhu, G., Wang, X., Wang, F., Mao, Y., Wang, H. (2017) New and Convergent Synthesis of Osimertinib. J. Heterocycl. Chem., 54: 2898–2901.

Data Availability

The datasets used and/or analyzed during the current study will be available from the authors upon reasonable request.

This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License. Authors who publish this series agree to the following terms:

1. Authors retain copyright and grant the series right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this series.

2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the series's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this series.

3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See Open Access Instruction).

Volume Title
Proceedings of the 2nd International Conference on Modern Medicine and Global Health
ISBN (Print)
978-1-83558-395-1
ISBN (Online)
978-1-83558-396-8
Published Date
10 July 2024
Series
Theoretical and Natural Science
ISSN (Print)
2753-8818
ISSN (Online)
2753-8826
DOI
10.54254/2753-8818/35/20240515
Copyright
10 July 2024
Open Access
This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited

Copyright © 2023 EWA Publishing. Unless Otherwise Stated